RA Capital Management, L.P. 13D and 13G filings for Inhibrx Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 4,724,352 9.990% |
870,485 (+22.59%) |
Filing |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 3,853,867 8.900% |
668,036 (+20.97%) |
Filing |
| 2022-10-17 5:21 pm Purchase |
2022-10-07 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 3,185,831 8.160% |
3,185,831 (New Position) |
Filing |
| 2021-05-17 4:33 pm Sale |
2021-05-17 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 0 0.000% |
-2,129,003 (Position Closed) |
Filing |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 2,129,003 5.600% |
2,129,003 (New Position) |
Filing |